The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma

Immune checkpoint inhibitors (ICIs), which have anti-tumor effects, are currently approved for treatment of several kinds of advanced malignancies. However, with their increasing use, a variety of immune-related adverse events (irAEs) in administered patients have been reported. We herein report a rare case of the simultaneous onset of acute pancreatitis and colitis as irAEs during nivolumab treatment given to a patient with renal cell carcinoma, who then shown marked improvement with corticosteroid therapy.

Automated summary

Immune checkpoint inhibitors (ICIs) have anti-tumor effects but can also result in a variety of immune-related adverse events (irAEs). This rare case report describes a patient with renal cell carcinoma who developed acute pancreatitis and colitis simultaneously as irAEs during nivolumab treatment, and showed significant improvement with corticosteroid therapy.